NYSE MKT LLC · AIM
-0.12% · -$0.0003 · Vol Not reported
Pre-market · updated 05:55:13 ET
AIM ImmunoTech Inc

AIM ImmunoTech Inc

Biotechnology
$0.2581
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
AIM
AIM ImmunoTech Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

55/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AIM moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AIM catalysts
About AIM ImmunoTech Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
1995
Employees
21
Country
US

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.2584
Last session
Day high
$0.2584
Last session
Day low
$0.2584
Last session
Previous close
$0.2584
52W high
$2.88
-91.03% from high
52W low
$0.2199
1% of range
Market cap
$7.9M
P/E
0.65×
EPS
$0.4000
Beta
-0.74
Shares out
30.4M
Avg volume
1.2M
VWAP
$0.2584
Last session
Price history computed in-house
1W
+6.21%
1M
+3.65%
3M
+10.92%
1Y
-90.43%
YTD
-77.14%
SMA 50 $0.2896 · below
SMA 200 $0.7851 · below
52W position 1%

AIM overview

Veridion Score
55
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AIM.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AIM Form 4 filings
Public disclosures

Congress activity in AIM

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AIM in the cached public ledger.

Federal contracts

AIM contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AIM in this window.
Lobbying spend

AIM lobbying filings, year to date.

Registered lobbying filings matched to AIM ImmunoTech Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AIM in this window.
Loading news for AIM
Analyst ratings
Sovereign unlock shows live analyst consensus for AIM.
Options
Sovereign unlock shows live options positioning for AIM.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.